In a continued push for increasing price transparency in healthcare, the Trump administration recently ...
For more than 25 years, the 340B Drug Pricing Program1 has helped safety-net facilities ...
As the global COVID-19 pandemic has progressed, so too have efforts to develop, manufacture, ...
In the past decade, advances in technology and progress in drug innovation have led ...
At CBI’s eighth annual Coupon & Copay Forum in October, industry experts gathered virtually ...
In September 2019, we discussed the definition and impact of the “Amazon Effect” in ...
Cell and gene therapies, collectively termed Advanced Therapy Medicinal Products (ATMPs) in the EU, ...
As the cost of pharmaceutical and biotechnology therapies continues to rise, concern about the ...
There is no question that prior authorization (PA) requirements around prescribed branded and specialty ...
At the end of June, Gilead announced its long-awaited pricing strategy for remdesivir, which ...
The urgency of the COVID-19 pandemic has illustrated how essential telehealth services are to ...
Value-based care, value-based contracting, outcomes-based contracting, risk-based contracting—the emergence of these strategies have left ...
When I was an access decision maker at a leading pharmacy benefit manager (PBM), ...